March Newsletter : Focus on Antibodies from CRB & Babraham Bioscience Technologies Ltd.

Having trouble seeing this email? View it in your browser instead.

March Newsletter:
Monoclonal Antibody Service
INFINITY Antibodies
Polyclonals

Cambridge Research Biochemicals has partnered with Babraham Bioscience Technologies Ltd & Epitomics Inc. to expand our offering to include monoclonal antibody services.

Monoclonals offer many advantages over traditional polyclonals:

Immortal cell line - antibody available in perpertuity
Defined specificity
Low non-specific activity
Ideal for low abundance antibodies, such as IgM
In-process assay optimisation
Ownership of cell line
Offers reproducibility & traceability

CRB provides the chemical insight and customer support by providing the peptide antigen (where required) and project management.

Emily Humphrys, CRB’s commercial director, said,

‘Our alliance means more options for our customers and access to unique technologies. We believe partnerships can make a real difference to drug discovery.'

Need to know more?

Why not visit our website for more information on Monoclonal Antibodies, you can also email us or fill out our contact form for a quote.

Our Monoclonal Antibody service is a way of generating antibodies in perpetuity. Once successfully made these antibodies can be duplicated time and time again to infinity.

Project Design:

Expert advice on the vital first step of antigen selection from either your target protein or peptide sequence
Design of screening strategy to select for clones against specific PTMs or protein regions
Choice of appropriate species